Treatment of Recurrent Urinary Tract Infections

521 patients suffering from frequent urinary tract infections were included in this study. Patients were treated for 3 months with one capsule daily of Uro-Vaxom, together with any eventual antibiotic or chemotherapeutic, and observed for further 3 months. During this 6-month trial the number of recurrences was significantly reduced in comparison with the 6month pretrial period ( P < 0.001). The high initial germ counts of both total and gram-negative germs were stabilized at a low level until the end of Uro-Vaxom therapy and remained low until the end of the trial ( P < 0.001 at both 3 and 6 months in comparison with initial values), as was also the case for the incidence of dysuria and pollakiuria ( P < 0.01). Total duration of antibiotic and chemotherapeutic administration followed this general improvement of the patients' condition. The product was well tolerated: side-effects were mentioned in 4.4% of the 521 patients, leading to treatment withdrawal in only two cases (0.4%). The overall efficacy of the test product was assessed by the physicians as positive in 80% of the cases both for its curative action beside the initial antibacterial treatment and for its consolidative long-term action until the end of the 6-month trial.